Skip to main content
About
Contact
Subscribe
e-Edition
Make Home Page
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Twitter
Toggle navigation
Site search
Search
Home
Contact Us
Advertise
Subscription Services
Promote Your Event
Submission Forms
News
Local News
National
World
Archives
Sports
Local Sports
National Sports
Business
Local Business
National Business
Technology
Markets & Stocks
Opinion
Columns
Editorials
Letters To The Editor
Polls
Thumbs
A & E
Local Entertainment
Art Scene
Music Scene
Theatre Scene
Book Reviews
Movie Reviews
TV Listings
Local Events
What To Do
Life
Health
Travel
Oddities
Community Directory
Community Service
Rescue Me
Other
Specials
Spring Home & Garden Show
Home & Realty
Outdoor Guide
Women
Spring on the Road
Spring Wellness
Premier Home Stylle Tour 2024
Classifieds
Place Ad
Careers
Tenders
Weather
Obituaries
2024 Auction
2024 Readersâ Choice Awards
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Urogen Pharma Ltd
(NQ:
URGN
)
17.50
+4.78 (+37.58%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Jun 13, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Urogen Pharma Ltd
< Previous
1
2
3
4
5
6
Next >
UroGen Pharma to Host UGN-102 Data Event on July 27, 2023
July 06, 2023
From
UroGen Pharma Ltd.
Via
Business Wire
Retrospective Study Reveals Lower Stricture Rate and Comparable Oncological Outcomes with Antegrade Administration of JELMYTO® Versus Retrograde Administration
June 20, 2023
From
UroGen Pharma Ltd.
Via
Business Wire
UroGen Pharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
June 09, 2023
From
UroGen Pharma Ltd.
Via
Business Wire
Recap: UroGen Pharma Q1 Earnings
May 11, 2023
Via
Benzinga
UroGen Pharma Earnings Preview
March 15, 2023
Via
Benzinga
UroGen Pharma's Return On Capital Employed Overview
December 20, 2022
Via
Benzinga
UroGen Pharma to Present at Upcoming Investor Conferences
June 02, 2023
From
UroGen Pharma Ltd.
Via
Business Wire
Earnings Scheduled For May 11, 2023
May 11, 2023
Companies Reporting Before The Bell • Takeda Pharmaceutical (NYSE:TAK) is likely to report earnings for its fourth quarter. • Exela Technologies (NASDAQ:XELA) is expected to report earnings for its...
Via
Benzinga
UroGen Pharma Meets Revenue Goal, Reports First Quarter 2023 Financial Results and Recent Corporate Developments
May 11, 2023
From
UroGen Pharma Ltd.
Via
Business Wire
UroGen Pharma to Report 2023 First Quarter Financial Results on Thursday, May 11, 2023
May 04, 2023
From
UroGen Pharma Ltd.
Via
Business Wire
First Study to Evaluate JELMYTO® Use Post-Complete Endoscopic Ablation Reports 69% of Patients were Disease Free at the Time of First Endoscopic Evaluation
May 01, 2023
From
UroGen Pharma Ltd.
Via
Business Wire
New Retrospective Study Presented at AUA 2023 Provides Evidence of Similar Outcomes Utilizing JELMYTO® in the Treatment of UTUC of the Ureter and Renal Pelvis
April 30, 2023
From
UroGen Pharma Ltd.
Via
Business Wire
UroGen Pharma to Present at H.C. Wainwright BioConnect Conference
April 25, 2023
From
UroGen Pharma Ltd.
Via
Business Wire
UroGen Pharma Reports Highest Revenue Quarter and Significant Full Year 2022 Growth and Recent Corporate Developments
March 16, 2023
From
UroGen Pharma Ltd.
Via
Business Wire
Earnings Scheduled For March 16, 2023
March 16, 2023
Companies Reporting Before The Bell • KVH Industries (NASDAQ:KVHI) is projected to report quarterly earnings at $0.03 per share on revenue of $34.29 million.
Via
Benzinga
UroGen Pharma to Report Fourth Quarter and Full-Year 2022 Financial Results on Thursday, March 16, 2023
March 09, 2023
From
UroGen Pharma Ltd.
Via
Business Wire
UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
March 06, 2023
From
UroGen Pharma Ltd.
Via
Business Wire
UroGen Pharma to Present at Upcoming Investor Conferences
March 01, 2023
From
UroGen Pharma Ltd.
Via
Business Wire
Investigational Therapy UGN-102 May Be Delivered at Home for the Treatment of Bladder Cancer
February 15, 2023
From
UroGen Pharma Ltd.
Via
Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For February 8, 2023
February 08, 2023
Via
Benzinga
Results of the First Post-Commercial Utilization Review of JELMYTO® Provide New Evidence that Reinforces its Efficacy and Safety in Patients with Low-Grade Upper Tract Urothelial Cancer
January 11, 2023
From
UroGen Pharma Ltd.
Via
Business Wire
UroGen Completes Enrollment of Its Phase 3 Clinical Trial for UGN-102 in Development for Low-Grade, Intermediate-Risk, Non-Muscle Invasive Bladder Cancer (LG-IR-NMIBC)
December 19, 2022
From
UroGen Pharma Ltd.
Via
Business Wire
UroGen Pharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
December 09, 2022
From
UroGen Pharma Ltd.
Via
Business Wire
UroGen Announces New Data from the OPTIMA II Study that Show Median Durability of Response of 24.4 Months for UGN-102, an Investigational Non-Surgical Chemoablative Treatment for Low-Grade, Intermediate-Risk Non-Muscle Invasive Bladder Cancer
December 02, 2022
From
UroGen Pharma Ltd.
Via
Business Wire
UroGen Announces New Data from the OLYMPUS Trial that Shows Median Durability of Response of 28.9 Months for JELMYTO®, the Only Non-Surgical, Chemoablative Treatment for Adults with Low-Grade Upper Tract Urothelial Cancer
December 01, 2022
From
UroGen Pharma Ltd.
Via
Business Wire
UroGen Pharma to Present at Evercore ISI 5th Annual Virtual HealthCONx Conference
November 21, 2022
From
UroGen Pharma Ltd.
Via
Business Wire
UroGen Highlights New Real-World Safety Data Published in The British Journal of Urology International That Showed a Low Rate of Ureteral Stenosis When Antegrade Administration of JELMYTO® was Used in Patients with Upper Tract Urothelial Carcinoma
November 14, 2022
From
UroGen Pharma Ltd.
Via
Business Wire
UroGen Pharma Reports Third Quarter 2022 Financial Results and Recent Corporate Developments
November 10, 2022
From
UroGen Pharma Ltd.
Via
Business Wire
UroGen Announces the Appointment of Dan Wildman to the UroGen Pharma Board of Directors
November 09, 2022
From
UroGen Pharma Ltd.
Via
Business Wire
Earnings Scheduled For November 10, 2022
November 10, 2022
Companies Reporting Before The Bell • IDEX Biometrics (NASDAQ:IDBA) is estimated to report earnings for its third quarter.
Via
Benzinga
< Previous
1
2
3
4
5
6
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.